Technoview® Arixtra® Calibrator Set
$0.00
Technoview® Arixtra® calibrator set is a set of plasma-derived calibration samples with Arixtra®* concentrations ranging from ~0-2 µg/ml. The set can be used for establishing a standard curve in research measurements of Arixtra®. It is optimized for use with anti-Xa chromogenic assays and is frequently used in conjunction with the Technoview® Arixtra® low and high controls in the Technochrom® anti-Xa chromogenic assay.
*Fondaparinux sodium is the active substance in Arixtra®.
| Calibrator 1 | 1 x 1 mL Technoview Arixtra Calibrator 1 (CAL 1), human plasma, lyophilized, no Arixtra |
| Calibrator 2 | 1 x 1 mL Technoview Arixtra Calibrator 2 (CAL 2), human plasma, lyophilized, ~0.5 µg / mL Arixtra |
| Calibrator 3 | 1 x 1 mL Technoview Arixtra Calibrator 3 (CAL 3), human plasma, lyophilized, ~1.0 µg / mL Arixtra |
| Calibrator 4 | 1 x 1 mL Technoview Arixtra Calibrator 4 (CAL 4), human plasma, lyophilized, ~1.5 µg / mL Arixtra |
| Calibrator 5 | 1 x 1 mL Technoview Arixtra Calibrator 5 (CAL 5), human plasma, lyophilized, ~2.0 µg / mL Arixtra |
Stability after reconstitution: 18-25°C (open vial) / 48 hours, 2-8°C (closed vial) / 7 days, -20°C / 1 month
Advantages
- Allows for establishment of calibration curve covering a range of 0-2 µg/ml
- Optimized for use with anti-Xa (without exogeneous antithrombin) research assays
Calibrator Set Composition
5 x 1 ml vials with a range of Arixtra® concentrations:
- Cal 1: 0 µg/ml
- Cal 2: 0.5 µg/ml
- Cal 3: 1 µg/ml
- Cal 4: 1.5 µg/ml
- Cal 5: 2 µg/ml
Calibrators are lyophilized and prepared from pooled human citrated plasma supplemented with different concentrations of Arixtra®. The plasma contains stabilizers but no bactericide additives. It is calibrated against the International Standard preparation 01/608.
Background
Arixtra® (fondaparinux sodium) Injection is a factor Xa (FXa) inhibitor drug. As a synthetic pentasaccharide, it is chemically similar to low molecular weight heparin (LMWH), though it is selective for FXa. More specifically, its high affinity antithrombin (AT) binding allows for indirect inhibition of FXa. Use of this drug substantially lowers the risk for heparin-induced thrombocytopenia (HIT) and it has not been shown to react with HIT antibodies. It is prescribed by a healthcare provider and can be used for:
- prophylaxis of venous thromboembolism (VTE) after major orthopedic or abdominal surgery; or
- treatment of acute VTE when administered in conjunction with warfarin i.e. used short-term until the warfarin blood test is in the target range.
In most cases, Arixtra® does not require routine monitoring. However, it can be measured using an anti-Xa assay with appropriate calibrators (fondaparinux sodium). The activity of fondaparinux sodium is expressed in mg and cannot be compared to the activities of heparin or LMWH. Note that this calibrator set is for research use only in the US and Canada.